BridgeBio Pharma

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $0.71 billion, up 196% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$0.44 billion.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.00 billion.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to December 31, 2025: $0.05 billion.SEC EDGAR filings (10-K)
• Long-term debt issued in the fiscal year to December 31, 2024: $0.45 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (August 10, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
• Latest annual report (filed February 24, 2026): 1 risk factor added, 3 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $19.2 million on the open market.SEC Form 4
• 475 institutional managers reported a position at June 30, 2026 (+14 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 6.U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for BridgeBio Pharma yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name BridgeBio Pharma, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

2 headlines

50% positive · 0% negative

90 days

2 headlines

50% positive · 0% negative

• Positive
  BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug (BBIO:NASDAQ)

  seekingalpha.com · via Marketaux · Oct 11, 2026

• Neutral
  FDA Grants Priority Review for BridgeBio Pharma's Oral Infigratinib NDA (BBIO)

  gurufocus.com · via Marketaux · Oct 6, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
2. Aug 17, 20268-K
   Material agreement signedItem 1.01
3. Jul 20, 2026Lobbying
   Lobbying report (BRIDGEBIO PHARMA, INC.)second_quarter 2026 · $0.5 million
4. Jul 17, 2026Lobbying
   Lobbying report (BRIDGEBIO PHARMA, INC.)fourth_quarter 2025 · $0.3 million
5. Jul 17, 2026Lobbying
   Lobbying report (BRIDGEBIO PHARMA, INC.)fourth_quarter 2024 · $0.3 million
6. Jul 17, 2026Lobbying
   Lobbying report (BRIDGEBIO PHARMA, INC.)first_quarter 2024 · $0.2 million
7. Jul 17, 2026Lobbying
   Lobbying report (BRIDGEBIO PHARMA, INC.)fourth_quarter 2023 · $0.1 million
8. Jul 9, 2026Lobbying
   Lobbying report (MARSHALL & POPP, LLC)second_quarter 2026 · $0.1 million
9. Jul 2, 20268-K
   Material agreement signedItem 1.01
10. Jun 26, 20268-K
    Director or officer changeItem 5.02
11. Jun 26, 20268-K
    Shareholder vote resultsItem 5.07
12. May 8, 20268-K
    Material agreement signedItem 1.01
13. May 8, 20268-K
    Material agreement terminatedItem 1.02
14. Apr 20, 2026Lobbying
    Lobbying report (BRIDGEBIO PHARMA, INC.)first_quarter 2026 · $0.4 million
15. Feb 24, 202610-K
    Annual report (10-K)1 risk factors added, 3 removed
16. Feb 3, 2026Patent
    Patent granted: FORMULATIONS OF AG10US 12539290
17. Jan 21, 20268-K
    Material agreement signedItem 1.01
18. Jan 13, 2026Patent
    Patent granted: TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORSUS 12522614
19. Oct 30, 2025Trademark
    Trademark application: JENRAYIS
20. Oct 30, 2025Trademark
    Trademark application: SUNFORLY
21. Oct 30, 2025Trademark
    Trademark application: JOYAGEM
22. Oct 30, 2025Trademark
    Trademark application: INFYPEARL
23. Oct 30, 2025Trademark
    Trademark application: LYFIGLO
24. Jul 15, 2025Patent
    Patent granted: METHODS OF TREATING CHOLANGIOCARCINOMAUS 12357632
25. Jul 15, 2025Patent
    Patent granted: FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDSUS 12357576
26. Jul 2, 20258-K
    Material agreement signedItem 1.01
27. Jun 23, 20258-K
    Shareholder vote resultsItem 5.07
28. Apr 22, 2025Patent
    Patent granted: BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORSUS 12281123
29. Mar 17, 20258-K
    Director or officer changeItem 5.02
30. Feb 28, 20258-K
    Material agreement signedItem 1.01
31. Feb 28, 20258-K
    Material agreement terminatedItem 1.02
32. Feb 20, 202510-K
    Annual report (10-K)3 risk factors added, 0 removed
33. Sep 30, 2024Private credit
    Loans held by business development companies (BridgeBio Pharma, Inc.)$300 million at cost
34. Feb 22, 202410-K
    Annual report (10-K)6 risk factors added, 4 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1743881

LEI

54930028YG89VTY2J114